Apyx Medical Corporation

APYX Healthcare Medical Devices

Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024. In the quarter to June 2026, revenue grew 22.1%, EPS grew 22.2%, free cash flow fell 137.4% and total debt rose 2.74%, each against the same quarter a year earlier.

2.55 0.01 −0.39%
Market cap
$107.8M
P/E
0.0×
Fwd P/E
−16.0×
Dividend yield
—
F-score
4/9
Altman Z
1.10
Beneish M
−2.63
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
3 4 4 3 4 4 2 4 2 4
P/E ratio
3.37 3.37 3.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
13.06 13.06 13.06 10.21 8.89 9.07 1.95 1.77 1.17 2.72
Altman Z-Score
— — — 13.50 14.87 18.54 2.58 0.89 (0.39) 1.10
Altman Z″-Score (non-manufacturers)
2.72 0.08 16.18 9.44 9.87 6.38 1.47 1.61 (0.95) (0.11)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 62.25 0.00 0.00
Beneish M-Score
(0.79) (3.99) (1.86) (0.35) (1.30) (2.58) (2.57) (3.48) (2.72) (2.63)
P/Operating CF
(12.08) (12.08) (12.08) (88.66) (242.21) 2,056.71 (19.20) (41.79) (19.12) (56.85)
P/B ratio
2.50 2.50 2.50 4.04 3.86 8.15 2.30 3.43 3.92 9.70
Price to Tangible BV
2.51 2.51 2.51 4.06 3.87 8.18 2.31 3.46 3.97 9.82
EV/Sales
8.38 8.38 8.38 8.16 7.40 8.44 1.73 1.74 1.40 2.95
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(6.70) (6.70) (6.70) (12.47) (12.76) (39.20) (3.80) (17.32) (3.73) (19.48)
EV/FCF
(6.58) (6.58) (6.58) (11.65) (12.31) (36.66) (3.62) 61.22 (3.58) (17.10)
Quick Ratio
3.79 2.60 9.68 5.56 6.47 3.94 2.40 4.53 4.40 4.15
Current Ratio
5.03 3.77 10.43 6.23 7.22 4.60 3.63 5.52 5.26 5.00
Net Debt/EBITDA
1.16 0.61 5.74 2.90 2.17 2.28 0.45 0.63 (0.12) (0.54)
Debt/Assets
8.07% 8.37% 0.15% 0.50% 0.25% 0.03% 0.14% 41.95% 52.32% 52.16%
Debt/Equity
0.11 0.12 0.00 0.01 0.00 0.00 0.00 1.23 2.37 2.35
Asset Turnover
0.27 0.31 0.26 0.31 0.35 0.68 0.74 0.80 0.67 0.80
Operating CF/Net income
0.72 0.73 (0.33) 0.94 1.35 0.69 0.87 0.28 0.77 0.71
Capex/Depreciation
(0.39) (0.90) (0.54) (1.73) (0.65) (0.80) (1.13) 9.73 (1.21) (1.70)
Interest Coverage
(72.10) (102.10) (137.27) (2,608.62) (436.59) (1,444.80) (1,570.80) (6.96) (3.19) (1.15)
ROE
(15.92%) (20.98%) 114.86% (24.88%) (17.61%) (25.74%) (50.51%) (57.83%) (113.74%) (76.88%)
ROA
(11.87%) (15.32%) 98.84% (21.81%) (14.98%) (21.24%) (38.48%) (28.57%) (32.57%) (17.03%)
ROIC
(51.51%) (62.17%) (98.67%) (101.36%) (56.73%) (38.99%) (53.21%) (65.34%) (71.30%) (22.44%)
Return on Tangible Assets
(14.25%) (22.39%) 72.08% (27.74%) (18.74%) (28.04%) (61.20%) (31.43%) (49.18%) (22.81%)
Average Days of Receivables
195.89 173.23 111.67 124.70 228.24 159.21 149.62 97.77 117.46 115.87
Research and Development Expense of Revenue
11.71% 18.97% 15.35% 13.21% 14.15% 8.91% 10.21% 10.39% 10.56% 6.38%
Selling, General and Administrative Expense of Revenue
175.47% 184.70% 135.82% 128.32% 121.49% 90.13% 108.18% 92.21% 89.65% 68.35%
Intangible Assets out of Total Assets
0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
9.17% 8.51% 13.39% 12.68% 15.19% 10.49% 15.05% 9.77% 8.34% 3.79%
Graham Net Nets
0.37 0.37 0.37 0.22 0.23 0.10 0.33 0.20 0.11 0.04
Graham Number
0.00 0.00 10.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
29.68% 29.68% 29.68% (6.62%) (4.86%) (3.43%) (26.59%) (20.22%) (42.41%) (7.71%)
Free Cash Flow Yield
(9.74%) (9.74%) (9.74%) (6.86%) (6.76%) (2.54%) (24.48%) 1.61% (33.42%) (6.34%)
Revenue per Share
0.32 0.33 0.50 0.83 0.81 1.41 1.29 1.51 1.35 1.29
Operating CF per Share
(0.10) (0.12) (0.63) (0.54) (0.47) (0.30) (0.59) (0.15) (0.51) (0.19)
Capex per Share
(0.01) (0.02) (0.01) (0.04) (0.02) (0.02) (0.03) 0.19 (0.02) (0.03)
Free Cash Flow per Share
(0.11) (0.14) (0.64) (0.58) (0.49) (0.33) (0.62) 0.04 (0.53) (0.22)
Cash per Share
0.56 0.34 2.36 1.73 1.23 0.90 0.30 1.26 0.89 0.77
Shareholders Equity per Share
0.96 0.70 2.63 2.09 1.87 1.57 1.09 0.78 0.40 0.36
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
0.96 0.70 2.63 2.09 1.87 1.57 1.09 0.78 0.40 0.36
Free Cash Flow
(3.12) (4.33) (21.24) (19.78) (16.65) (11.17) (21.29) 1.49 (18.77) (9.11)
Working Capital
21.27 16.57 81.22 64.42 56.94 47.53 31.12 57.62 45.72 46.77
Capital Expenditures
(0.29) (0.62) (0.36) (1.30) (0.58) (0.72) (1.01) 6.73 (0.72) (1.11)
Net Current Asset Value
17.65 13.59 81.08 63.25 55.84 46.03 28.99 18.04 5.93 6.46
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.06 0.02 0.05 0.02 0.01 0.02 (0.13) 0.02 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.11 0.12 0.12 0.11 0.14 0.14 0.13 0.36 0.30 0.28
Cash ROIC
(7.05%) (12.26%) (12.83%) (15.15%) (15.71%) (13.16%) (44.30%) 1.43% (23.46%) (11.19%)
Accounts Receivable Turnover
2.30 2.13 3.34 3.83 2.05 2.52 2.26 3.24 3.26 3.28
Accounts Payable Turnover
2.63 2.05 3.85 4.74 5.17 7.20 5.80 6.91 7.04 6.98
Inventory Turnover
0.61 0.63 1.56 2.23 2.24 2.75 1.66 1.71 2.14 2.45
Average Days of Payables
158.30 176.37 89.88 97.35 54.03 64.38 63.35 53.25 50.93 56.37
Days of Inventory on Hand
606.99 476.19 198.70 202.37 144.86 165.86 279.99 194.83 147.31 158.57
Average Receivables
3.83 4.80 4.97 7.36 13.49 19.25 19.70 16.13 14.75 16.13
Average Payables
1.41 1.59 1.50 1.93 1.97 2.07 2.65 2.69 2.66 2.84
Average Inventory
6.06 5.22 3.71 4.11 4.56 5.41 9.29 10.86 8.74 8.08
Average Assets
33.28 33.05 63.46 90.34 79.43 71.42 60.25 65.51 72.04 65.84
Average Common Equity
24.81 24.13 54.60 79.22 67.56 58.93 45.90 32.36 20.63 14.58

Fold the line items

Columns are period end dates